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The impact of the success of organised cervical screening programme results in a steady decline of the incidence of squamous cell
carcinoma of the cervix but a concomitant increase in the incidence of the less common histological subtypes, particularly
adenocarcinoma of the cervix (ACC). Although Human papillomavirus (HPV) infection is believed to be a necessary cause of cervical
cancer, its role in the pathogenesis of ACC is not well established. Established associations between oncogenic strains of HPV and
ACC are based on molecular studies carried out on entire tumour block sections. In this study, the cervical adenocarcinoma cells of a
10-year cohort of women diagnosed with ACC were dissected using the PixCell II Laser Microdissecting System to detect the HPV
16 genome sequence using the real-time quantitative polymerase chain reaction to confirm the presence of HPV DNA within ACC
cells. By coupling these two sophisticated techniques, the HPV DNA copy number cell could be calculated to investigate its role. The
prevalence of HPV 16 infection in this cohort was 24%, which is significantly higher than the control group (w
2, P¼0.014). Women
with ACC also had significantly higher HPV DNA copy number per cell compared to the control group (P¼0.00007). Higher HPV
DNA copy number is associated with risk of developing ACC.
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In countries such as the United Kingdom, organised cervical
screening has resulted in a steady decline in the overall incidence
of cervical cancer. Cervical screening has enabled identification
and treatment of squamous epithelial changes in its pre-malignant
state, leading to a noted decline in the incidence of squamous cell
carcinoma (SCC) in all age groups. Conversely, there is a
concomitant rise in the incidence of ACC. This is largely due to
a relative increase, but there is evidence of an absolute increase in
the incidence of ACC in more recent birth cohorts (Sasieni and
Adams, 2001); particularly in women aged less than 35 years old.
HPV infection is necessary for the development of cervical
cancer (Walboomers et al, 1999). While the role of HPV in the
pathogenesis of ACC is less well understood, the association of
HPV infection in ACC and in antecedent cervical cytology have
been reported (Xavier-Bosch et al, 1995). HPV infection is highly
prevalent and is usually transient. It is effectively cleared by the
immune system 90% of the time, suggesting that other biological,
environmental and viral-specific factors must trigger the malig-
nant transformation.
HPV infection has a defined role in the aetiology of squamous
intra-epithelial changes. The incidence of concurrent intra-
epithelial changes in the presence of ACC is quoted as high as
40% (Maier and Norris, 1980). In a study where the presence of the
HPV subtypes were identified using immunohistochemical ex-
pression of the p53 gene product, HPV16 infection was found in
the adjacent uninvolved cervical squamous epithelium (Ferguson
et al, 1998). It is therefore possible that the incidence of HPV
infection in ACC has been exaggerated in studies where HPV
infection was identified in DNA extracted from sections of tumour
blocks.
A possible solution would be to employ the sophisticated
technology afforded by the laser capture microdissecting (LCM)
system, which selects specific cell of interest for analysis, with
minimal loss and destruction of DNA material (Curran et al, 2000).
In this study, we coupled two sophisticated mechanisms of LCM
and real-time quantitative PCR (RTqPCR) to define the presence
and amount of HPV16 DNA in cervical adenocarcinoma cells.
MATERIALS AND METHODS
Chemicals
PCR grade Proteinase K digest is purchased from Roche.
The Tween 20 (Polyxyethylene Sorbitane) and Ethylenediamine
tetraacetic acid (EDTA) were purchased from Sigma. The
DNA extraction buffer comprised a mixture of 50mM Tris/HCl
(pH8.5), 1mM EDTA. The Nucleon BACC II DNA extraction
kit used was from Tepnel Life Sciences, Manchester, UK.
The TAQMAN Universal PCR Mastermix, Passive Reference
and optimised buffer components was from Applied Biosystems,
CA, USA.
Received 4 April 2005; revised 20 July 2005; accepted 3 October 2005;
published online 1 November 2005
*Correspondence: Dr GK Chew, Department of Obstetrics and
Gynaecology, Northampton General Hospital, Northampton NN1
2BG, UK; E-mail: Kheng.Chew@ngh.nhs.uk
British Journal of Cancer (2005) 93, 1301–1304
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sEthics
We obtained permission from the Grampian Research Ethics
Committee to identify the cases and controls from the Grampian
University Hospitals (GUH) pathology database and to use
archival paraffin-fixed specimens for analysis.
Case and control samples
Using the GUH population-based pathology database, a cohort of
women diagnosed with ACC between 1991 and 2000 were
identified. The archival paraffin-embedded tissue blocks were
retrieved from the GUH tissue bank and reviewed by two
consultant pathologists to confirm the histopathological diagnoses.
Age-matched controls were identified from women who had
undergone hysterectomy or amputation of cervix in 1991–2000.
Four controls were selected for each case by year of operation and
their date of birth were matched to within 24 months of their case.
The tissue sections were prepared for laser microdissection as
follows: 5mm sections were cut onto glass slides and dried
overnight. The sections were dewaxed and stained with 0.25%
Touloudine blue (pH4.5). The cells were microdissected using the
Pixcell II Laser Microdissection System (Arcturus Engineering, CA,
USA) using the following settings: laser pulse spot 15mm, voltage
100mW and duration of laser exposure 10.0 milliseconds.
Approximately 500 pulses are taken per tumour sample.
The adenocarcinoma cells were dissected and used for the cases.
For the controls, the columnar epithelium was microdissected to
avoid contamination of possible HPV infection in the squamous
epithelium. The squamous epithelial cells were laser micro-
dissected and the DNA extracted from these cells to analyse for
the HPV 16 gene sequence.
The transfer film containing the dissected cells was removed
from the vial cap (CapSuret HS, Arcturus Engineering, CA, USA)
and incubated in a proteinase K digest (Tween, Proteinase K and
digest buffer) on a heating block at 551C and then heat inactivated
at 981C. DNA extracted from these cells was stored at 41C for
sequence analysis.
Laser capture microdissection system
The Pixcell II Laser Microdissection System (Arcturus Engineer-
ing, CA, USA) is an inverted microscope with an infrared
dissection laser, which targets the sample from above. The cells
are transferred onto a transfer film, which is permanently bonded
to the underside of a transparent vial cap (CapSuret HS).
Real-time quantitative PCR
The ABI 7700 PRISM
s Sequence Detector (Applied Biosystems,
CA, USA) enables real-time quantitative PCR (RTqPCR) analysis
for particular gene sequences to allow quantitation of PCR
product.
Probes and primers
The primer and probe sets for RTqPCR were designed using the
Primer Express 1.0 software. The complete genome sequences of
HPV16 (accession number NC 001526) and Beta-globin (accession
number NG 000007.2) gene were entered into the programme to
design primer and probe sets optimal for the ABI7700 PRISM
s
sequence detector (Applied Biosystems, CA, USA). A BLAST
search was performed (http://www.ncbi.nlm.nih.gov/BLAST) for
each primer and probe oligonucleotide sequence to confirm
specificity for the target locus. The probe was labelled with the
fluorescent reporter molecule FAM, which emits as the PCR
product is formed. The specific primer and probe sets were
ordered from Applied Biosystems. The Beta-globin primer and
probe sets had been used successfully with the ABI7700 Sequence
Detector (Rooney, 2005).
CaSki cell line growth condition
The CaSki cell line was cultured in Dulbecco’s medium (Life
Technologies) supplemented with 10% (v/v) fetal calf serum (FCS)
in a 371C incubator with 5% CO2/95% air with media changes
twice weekly. Cultured cells were passaged weekly using PBS
(Oxoid), followed by detachment of the cells using a mixture of
trypsin/EDTA and then incubated at 371C for 5min. The cells are
pelleted and seeded into sterile flasks where they were washed with
ice-cold PBS and scraped into 10ml ice-cold PBS. 100ml of the cell
suspension is removed and added to 100ml of Trypan buffer. Once
the cells were counted using a haemocytometer, the suspension
was centrifuged to give a pellet.
Real-time quantitative PCR
The DNA templates were assessed for HPV16 gene copy by real-
time quantitative PCR using the ABI7700 sequence detector
(Applied Biosystems, CA, USA). Beta-globin gene sequence was
used as a reference gene, the positive PCR product confirmed
successful DNA extraction. A no-template triplicate was used as a
negative control. DNA extracted from CaSki cell line pellet using
the Nucleon BACC II method (Tepnel Life Sciences, Manchester,
UK) was used as positive control. Each CaSki cell contains 600
copies of the HPV16 gene (Meissner, 1999).
A standard curve was generated for HPV 16 and Beta-globin
DNA copy numbers using the average CT generated by quantitative
PCR analysis of serially diluted DNA extract of a known numbers
of Caski cells (Figure 1). Each sample of DNA template was
analysed in triplicate for both Beta-globin and HPV16 DNA
sequence for 40 cycles. The average CT for HPV16 and Beta-globin
of each sample were plotted, respectively, on the standard curve to
calculate the DNA copy number. The HPV 16 DNA copy per cell is
calculated by the ratio of the HPV 16 to Beta-globin copy number.
Classification of HPV 16 DNA copy number
In this study, DNA copy number of o100 copies per cell was
classified as low HPV 16 DNA copy number. DNA copy number of
X100 copies per cell as high HPV16 DNA copy number (Table 1).
Statistical analysis
The 2 2 w
2 tests were used to evaluate the risk of HPV 16
infection and the HPV 16 DNA copy number on the risk of
developing ACC. A probability value of o0.05 was considered
The standard curve for HPV16 and Beta-globin correlating the
DNA copy number to CT values
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Figure 1 Standard curve for HPV 16 and Beta-globin.
HPV 16 in adenocarcinoma of cervix
GK Chew et al
1302
British Journal of Cancer (2005) 93(11), 1301–1304 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
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6.04b January 1997 package (A word Processing Database and
Statistics Programme for Public Health, Centre for Disease Control
and Prevention and World Health Organisation, Geneva, Switzer-
land).
RESULTS
A total of 55 cases of ACC were identified from the GUH pathology
population-based database. The age distribution showed a bimodal
pattern, with peaks in the 36–45 and over 55 years age groups
(Figure 2). In all, 82% of the ACC were well or moderately
differentiated cancer (Table 2). In all, 208 controls were identified.
Successful DNA extraction, defined by presence of Beta-globin
gene sequence, was found in all the samples. Real-time quantitative
PCR analysis showed that 24% (13/55) of the cases were HPV 16
positive. In the control group, 21/208 (10%) were positive for
HPV16. HPV 16 infection was 2.7 times more likely to be found in
ACC cells than in the control group and this finding is statistically
significant (Table 3). (w
2 P¼0.014; Yates – corrected) Odds
Ratio¼2.76 (95% CI 1.19–6.33).
In HPV 16 positive ACC cases, 77% had low DNA copy
numbers. All the HPV 16 positive controls had low DNA copy
numbers. The HPV 16 DNA copy number per cell is significantly
higher in the HPV 16 positive ACC cells compared to the controls
(see Table 4) (w
2 P¼0.00007). There was no statistical difference in
the HPV copy number in the grade of the cancer (Table 2). The
HPV 16 DNA copy number is significantly higher in women over
45 years old (P¼0.03) (Table 5).
The squamous epithelium adjacent to the cervical adenocarci-
noma cells was analysed separately for HPV 16 infection. In all, 39
specimens had squamous epithelium in the archival specimens; the
remaining 16 samples were punch biopsies of the endocervix and
had no adjacent squamous epithelium in the archival specimens.
In all, 10 of the 39 cases with adjacent squamous epithelium for
analysis, had HPV 16 in the adenocarcinoma cells. Seven
squamous epithelium specimens were positive for HPV infection.
Of this, three had HPV 16 infection in both squamous and
columnar epithelium. All three had low HPV 16 DNA copy number
in the squamous epithelium. All three women were over 40 years
old at the time of their diagnosis. Although the frequency of
simultaneous infection is higher, the association is not statistically
significant.
DISCUSSION
The key finding in this study is the direct demonstration of HPV
16 DNA within the cervical adenocarcinoma cells. It confirmed the
infection of the adenocarcinoma cells and therefore allowed the
demonstration of the true prevalence of HPV16 infection in ACC.
This added significant strength to the link between HPV 16
infection and the aetiology of adenocarcinoma of the cervix. The
demonstration of HPV 16 infection in the adjacent squamous
epithelium but not in the adenocarcinoma cells, supports our
hypothesis that the previously recorded high prevalence of HPV 16
infection in ACC is due to infection in adjacent squamous
epithelium.
We have shown that using the LCM technique of tissue selection
for analysis, a higher yield of DNA extraction is achieved. The
specificity is also increased as we can confirm that the HPV 16
Table 1 Classification of HPV 16 DNA copy number
DNA copy number
Low count High count
0.1 100
1 1000
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Figure 2 The age distribution of women with ACC (1991–2000). The
shaded areas represent HPV 16 positive women.
Table 2 The HPV DNA count in the well, moderately or poorly
differentiated Adenocarcinoma of the cervix
Low HPV16 High HPV 16 HPV 16 neg
Well 6 1 13
Moderate 3 2 19
Poor 1 0 7
Total 10 3 39
Table 3 HPV 16 in ACC cases and age-matched controls
Cases Controls
HPV 16 + 13 21
HPV 16   42 187
P¼0.014 (w
2; Yates – corrected) Odds Ratio¼2.76 (1.2 oOR o6.3) 95% CI 1.19–
6.33.
Table 4 HPV 16 copy number in cases and controls
ACC cases Age matched controls
High HPV 16 DNA copy no. 4 0
Low HPV 16 DNA copy no. 9 21
(w
2test) P¼0.00007.
Table 5 HPV 16 DNA copy number according to the woman’s age at
time of diagnosis
Age o35 36–45 46–55 455
HPV16   32 1 41 4
HPV16 (low) 2 6 2 0
HPV16 (high) 0 0 2 1
Fisher 1-tailed w
2 P¼0.03; RR¼5; 1.45oRR o17.27.
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HPV 16 DNA in concurrent CIN can also be avoided. We also
decrease the false negative rates by reducing the loss by dilution
effect. By extracting DNA only from the tumour cells, the amplified
PCR product has a higher concentration of HPV DNA.
Previously published studies were based on a qualitative analysis
of presence or absence of the PCR product. By using real-time
quantitative PCR, the cycle by cycle detection of accumulated PCR
product allows us to generate a standard curve, in order to
calculate the gene DNA copy number. In conjunction with the
LCM, for the first time, we are able to expand our understanding of
HPV infection in ACC by studying the effect of HPV DNA viral
load on the cancer cells.
Women with ACC are 2.7 times more likely to have HPV 16
infection compared to the control population and have a higher
HPV DNA copy number than the controls. The prevalence of HPV
16 infection in our control population is 10%, which is consistent
with epidemiological studies and all of these women had a low
HPV 16 DNA copy number. This finding strongly supports the
theory that most HPV16 infection is transient (Schiffman, 1992)
and higher HPV DNA copy number is associated with develop-
ment of cervical carcinoma (Ylitalo et al, 2000).
Over half of the HPV 16 positive samples came from women
under 45 years old, which reflects the sexually transmissible nature
of the infection. By using real-time quantitative PCR, we have
demonstrated the variation in HPV 16 copy number across this
population. The DNA copy number, however, is higher in women
over 45 years old. One possible explanation for this finding is DNA
replication during the longer incubation period of HPV16 infection
before transformation to malignancy (Stanley, 2001). The lower
HPV DNA copy number in the women under 45 years old may be
explained by infection of multiple HPV subtypes or infection by
high risk HPV 16 subtypes.
Direct infection of columnar cells is the main route of HPV 16
infection, as only 27% of the HPV 16 positive cases have
concurrent infected squamous epithelium. This lower prevalence
on concurrent HPV infection in the squamous epithelium can be
explained by clearance of HPV infection from the squamous
epithelium. In Stanley’s immunobiological model on HPV infec-
tion of squamous epithelium, HPV infection is targeted at the basal
epithelial cells. It is possible that the infected basal cells, of
Stanley’s biological model, could have differentiated into glandular
epithelial cells and therefore the squamous cell will bear no
evidence of HPV infection.
By coupling the two powerful techniques of laser capture
microdissection and real-time quantitative polymerase chain reac-
tion, we were able to demonstrate a more accurate picture of the role
of HPV infection in the pathogenesis of cervical adenocarcinoma.
Accession number for the genomes
National Center for Biotechnology Information database (http://
www.ncbi.nlm.nih.gov/BLAST).
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